Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 1.00 |
| ▸ | PGR | P06401 | 17/20 | 1.00 |
| ▸ | AR | P10275 | 13/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861542 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL20048338 | 0.92 | NR3C1 (0.85) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL19042733 | 0.92 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL22861552 | 0.92 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL19042685 | 0.92 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL22861575 | 0.91 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL19042671 | 0.91 | NR3C1 (1.00) | NR3C1PGRARCYP2C8CYP3A4 | |
| SCHEMBL19042776 | 0.90 | NR3C1 (0.84) | NR3C1PGRARCYP2C8THRB | |
| SCHEMBL19042730 | 0.90 | NR3C1 (0.84) | NR3C1PGRARCYP2C8THRB | |
| SCHEMBL22861585 | 0.89 | NR3C1 (1.00) | NR3C1PGRARCYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208432-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210002324-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2017112909-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208432-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 61/4885AR 13/4885 |
| US-20210002324-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 61/4885AR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.